Goldman Sachs Boosts Guardant Health Target Price to $225
Goldman Sachs analyst Evie Koslosky has reaffirmed her buy rating on Guardant Health (GH.US), adjusting its target price to $225 from $210. According to TipRanks data, Koslosky has a success rate of 73.9% and an average return of 12.4% over the past year. This means that out of her total ratings, she was correct about 73.9%, resulting in an average profit of 12.4%. The analyst's performance is represented by a 5-star rating from TipRanks, indicating excellent past results.
Koslosky's new target price suggests a significant increase in the stock's value, implying that she believes Guardant Health has strong growth potential. This opinion is based on her analysis of the company's financials and market trends. It's worth noting that Koslosky's success rate is impressive, indicating that her recommendations have been accurate and profitable for investors.